BDX logo

BECTON DICKINSON AND CO

BDXNYSE
πŸ† #267 by market capEarnings Nov 5US Equity
$195.16β–² $0.14 (+0.07%)
πŸŒ™ After hours$195.16β–² 0.00%Regular close Β· extended-hours price shown
πŸ””
Track BDX
Get earnings, price moves & breaking news on Telegram
Track
24hβ–² 0.1%
7dβ–Ό 2.6%
14dβ–² 0.7%
30dβ–² 7.2%
ytdβ–² 0.6%
1yβ–² 7.5%
🏦Market Cap
$53.16B
Mid Cap
πŸ“ˆRevenue Growth (YoY)
8.2%
Slowing
πŸ“ŠGross Margin
46.1%
Healthy
πŸ’΅FCF Margin
12.5%
Healthy
βš–οΈP/S Ratio
2.6x
Cheap
Otter Score
84
Strong

Trading Snapshot

Day Range
$193.80 – $196.88
52-Week Range
$127.59 – $200.47
Volume (shares)
1,740,440
Avg Volume (shares)
β€”
Shares Outstanding
272.4M
Next Earnings
2026-11-05

Fundamentals Snapshot

Annual Revenue
$21.84B
Last Q Revenue
$4.98B
P/E Ratio
58.8
P/S Ratio
2.6x
EPS (TTM)
$3.42
Dividend Yield
2.04%
Dilution (1yr)
βˆ’1.8%
BDX logo

BECTON DICKINSON AND CO

BDX
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$21.8Bβ–² +8.2% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
45.4%β–² +0.5% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$2.6Bβ–² +7.6% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$2.7Bβ–Ό βˆ’13.1% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
285.1Mβ–Ό βˆ’1.8% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$18.5Bβ–Ό βˆ’$468M YoY
StockOtter Β· stockotter.space

About BECTON DICKINSON AND CO

Operating globally, Becton, Dickinson and Company (BD) is a prominent enterprise focused on the development, manufacturing, and distribution of a broad spectrum of medical technology. This includes essential medical supplies, sophisticated devices, advanced laboratory equipment, and critical diagnostic products. Its extensive customer base comprises healthcare providers, clinical institutions, medical researchers, pharmaceutical firms, and the general public around the world. The BD Medical division delivers a comprehensive suite of products primarily focused on medication management and drug delivery. This encompasses a variety of intravenous (IV) access solutions, such as peripheral and advanced catheters, central lines, acute dialysis catheters, and related vascular care items including needle-free connectors and closed-system drug transfer devices. It also provides essential injection equipment like hypodermic syringes, needles, anesthesia trays, enteral syringes, and sharps disposal systems. Additionally, this segment develops integrated systems for IV medication and infusion therapy, medication compounding workflow, automated dispensing, and supply chain optimization. Specialized products for diabetes management, including pen needles, along with prefillable drug delivery systems, are also key offerings. BD Life Sciences focuses on diagnostic and research tools, offering products for specimen and blood collection. This segment supplies automated systems for culturing blood and tuberculosis, molecular testing, microorganism identification, and drug susceptibility analysis. It also provides liquid-based cytology systems, rapid diagnostic assays, microbiology laboratory automation, and plated media. Furthermore, it offers advanced solutions for cell analysis, including fluorescence-activated cell sorters and analyzers, antibodies, kits, and reagent systems. These are crucial for single-cell gene expression analysis, as well as for clinical oncology, immunological, and transplantation diagnostics and monitoring. Finally, the BD Interventional segment delivers specialized products for surgical and interventional procedures. Its portfolio includes solutions for hernia and soft tissue repair, biological and bioresorbable grafts, and biosurgery, alongside other surgical products. This segment also addresses surgical infection prevention, provides a range of surgical and laparoscopic instrumentation, offers peripheral intervention products, and supplies urology and critical care devices. Established in 1897, the company maintains its headquarters in Franklin Lakes, New Jersey.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Strong
84/100
Analyst data unavailable.

Latest News & Updates

PRNewsWireΒ·18h ago

BD Advances Portal Hypertension Care in the U.S. with Support for More Personalized Treatment Options

The launch of theΒ Livertyβ„’ TIPS Stent Graft gives physicians flexibility to tailor treatment for patients. FRANKLIN LAKES, N.J.

Defense WorldΒ·21h ago

Citizens Financial Group Inc. RI Purchases 4,390 Shares of Becton, Dickinson and Company $BDX

Citizens Financial Group Inc. RI increased its position in shares of Becton, Dickinson and Company (NYSE: BDX) by 129.5% during the undefined quarter, according to its most recent filing with the Securities and Exchange

Seeking AlphaΒ·23h ago

First Eagle Global Fund Q3 202 Portfolio Update

Global Fund A Shares (without sales charge) posted a return of 2.10% in third quarter 2026. Leading contributors in the First Eagle Global Fund this quarter included Workday, Inc. Class A, Meta Platforms, Inc. Class A, S

Seeking AlphaΒ·2d ago

First Eagle U.S. Value Fund Q3 2026 Portfolio Review

U.S. Fund A Shares (without sales charge) posted a return of 4.36% in third-quarter 2026. The US Fund outperformed the S&P 500 Index in the period. Shares of Meta performed well following the strong reception of Muse, it

Seeking AlphaΒ·2d ago

Best Dividend Kings: October 2026

Dividend Kings have outperformed SPY YTD, rising 13.5% versus SPY's 12.32%, with a strong October rebound. Twenty-six Dividend Kings appear both potentially undervalued and offer long-term annualized expected returns of

Seeking AlphaΒ·5d ago

The Dividend Aristocrats Ranked By Quality Scores (October 2026)

I rank all 69 S&P 500 Dividend Aristocrats by my 9F Quality Scores, segmenting them into undervalued, fairly valued, and overvalued groups. My consensus fair value estimates, blending up to 40 data points per stock, high